# Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

> **NCT02725606** · PHASE1 · UNKNOWN · sponsor: **Jiangsu T-Mab Biopharma Co.,Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Chemotherapy-induced Neutropenia

## Interventions

- **BIOLOGICAL:** Pegylated Recombinant Human G-CSF
- **BIOLOGICAL:** GW003

## Key facts

- **NCT ID:** NCT02725606
- **Lead sponsor:** Jiangsu T-Mab Biopharma Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02725606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02725606, "Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02725606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*